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Abstract: The type 2 dopamine receptor D2 (D2-R), member of the G protein-coupled receptor (GPCR)
superfamily, exists in two isoforms, short (D2S-R) and long (D2L-R). They differ by an additional
29 amino acids (AA) in the third cytoplasmic loop (ICL3) of the D2L-R. These isoforms differ in
their intracellular localization and trafficking functionality, as D2L-R possesses a larger intracellular
pool, mostly in the endoplasmic reticulum (ER). This review focuses on the evolutionarily conserved
motifs in the ICL3 of the D2-R and proteins interacting with the ICL3 of both isoforms, specifically
with the 29 AA insert. These motifs might be involved in D2-R exit from the ER and have an
impact on cell-surface and intracellular localization and, therefore, also play a role in the function
of dopamine receptor signaling, ligand binding and possible homo/heterodimerization. Our recent
bioinformatic data on potential new interaction partners for the ICL3 of D2-Rs are also presented.
Both are highly relevant, and have clinical impacts on the pathophysiology of several diseases such
as Parkinson’s disease, schizophrenia, Tourette’s syndrome, Huntington’s disease, manic depression,
and others, as they are connected to a variety of essential motifs and differences in communication
with interaction partners.
Keywords: D2 dopamine receptor; intracellular trafficking; endoplasmic reticulum; retention motifs;
ICL3; interacting partners
1. Dopamine Receptors
G-protein-coupled receptors (GPCRs), also termed seven-transmembrane receptors (7TMRs) are
by far the largest family of membrane-bound receptors, which are involved in the regulation of the
neurotransmitter dopamine effects as one of their targets [1]. Based on functional, structural, and
pharmacological properties, five types of dopamine receptors have been described, that belong to
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the D1- or D2-like subfamily of receptors (D1-R and D2-R respectively), with differing abilities of
stimulation or inhibition of adenylyl cyclase (AC), respectively.
The D1-R subfamily is comprised of D1 and D5 receptors (D1-R and D5-R), and the D2 subfamily
includes D2, D3 and D4 receptors (D2-R, D3-R, and D4-R). Members of the D1-R subfamily have a
short third cytoplasmic loop (ICL3) and a very long C-terminal cytoplasmic end. In contrast, D2-Rs
have a very long ICL3 and a short C-terminal end and include the receptor variants generated by
alternative splicing (D2 and D3) or polymorphic variation (D4) (reviewed by Beaulieu et al.) [2].
The D2-R subgroup has a long ICL3 whose structure is common to the receptor interaction with the
heterotrimeric protein Gαi [1]. In D1-R, with its characteristically short ICL3, coupling with Gαs
proteins occurs [1,3]. The C-terminal end is approximately seven times longer in D1-Rs than in D2-Rs.
Both the ICL3 and the C-terminal end are thought to serve as possible communication points for
interaction with intracellular proteins. The N-terminal tail has a similar number of amino acids in all
receptor subtypes and contains sites for N-glycosylation. D1-R and D5-R have two glycosylation sites,
located at the N-terminal end and in extracellular loop 2 (ECL2). D2-R has three potential N-linked
glycosylation sites, all in the N-terminus: N5, N17, and N23, D3-R has four potential glycosylation sites:
N12 and N19 in the N-terminus, N97 in the first extracellular loop (ECL1), and N173 in the second
extracellular loop (ECL2) [4] and D4-R only one in the N-terminus [5]. Cysteines located in the first and
second extracellular loops (ECL1 and ECL2) are linked by a disulfide bond that stabilizes the receptor
structure [6]. The endogenous ligand for the dopamine receptors is the neurotransmitter dopamine.
After dopamine binds to the D1-R, the signaling pathway is canonically activated via the heterotrimeric
protein Gαs and Golf G-proteins, leading to adenylate cyclase (AC) activation and cyclic adenosine
monophosphate (cAMP) formation in the cell. Diversity in functional outcomes may also be achieved
via selective binding to Gαi and Gαo proteins. Previous work has shown that D2-R can be stabilized
by an agonist, which affect the selectivity and amount of coupling with Gαi and Gαo [7,8]. Although
previous work had indicated that Gαi2 was selective for D2L-R [9,10], experimental data has indicated
that selectivity regulation of Gαi is driven by the agonist-activated conformation of D2-R. R(+)-3-PPP
hydrochloride stimulation of D2-R resulted in reduced coupling with Gαi1 or Gαi2 and preferential
coupling with Gαi3 [11]. The movement magnitude of the sixth transmembrane helix of the activated
receptor was predicted to be the primary modulator of the selectivity of the G-protein subtypes [12].
Using cryo-electron microscopy, the structure of an agonist-bound activated D2–Gαi complex
reconstituted into a phospholipid membrane has been demonstrated recently [13], both as the first
experimental model of a GPCR complex embedded in a phospholipid bilayer, as well as the first
model of activated D2-R. The models revealed interactions that are unique to the membrane-embedded
complex, such as conformational changes in ECL2, TM5, TM6 and TM7, propagating to the opening of
the intracellular Gαi-binding site and helix 8 burial in the inner leaflet, ordered lysine and arginine side
chains in the membrane interfacial regions, and lipid anchoring of the G-protein in the membrane [13].
Although all D-Rs recognize the same ligand, they have a differential tissue distribution and
are involved in different functions in vivo [3,14]. By binding to various types of D-Rs, dopamine
controls locomotor system functions, cognition, emotion, hunger, satiety, and endocrine secretion [3,5].
Impaired D2-R signaling is associated with the pathophysiology of many psychiatric and neurological
diseases or states, including Parkinson’s disease, schizophrenia, Tourette’s syndrome, Huntington’s
disease, bipolar disorder, depression, dementia, as well as others, such as restless leg syndrome and
sexual dysfunction. D-Rs are an essential target for currently available modern drugs, including
the dopamine precursor levodopa [3,5] for Parkinson’s disease, where dopaminergic neurons are
damaged and a dopamine deficiency leads to a combination of movement and psychiatric pathologies.
Thus, D-Rs are targets for motor deficits, cognitive, and motivational deficits in neuropsychiatric
disorders [15]. In schizophrenia and psychosis inhibitors of D2-R are used to reduce increased
dopaminergic signaling [16].
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2. Dopamine Receptor Type 2 (D2-R)
The D2-R is a key component of the dopamine system that is present in two alternatively spliced
transcripts of the Drd2 gene and classified as short (D2S-R) and long (D2L-R) receptor isoforms. The long
isoform differs from the short one only by the presence of an additional 29 amino acids (AA) encoded
by exon 5 in the ICL3 of the D2L-R [17–19]. The inclusion is interspersed between the AA lysine
(K241) and glutamic acid (E271). D2S-R in mice and rats are made up of 415 AA and D2L-R is made
up of 444 AAs. Human D2S-R and D2L-R are shorter than murine and rat equivalents by one AA,
consisting of 414 and 443 AAs, respectively. The isoleucine is missing between lysine (K331) and
aspartic acid (D332). This region might have an essential role in the functional differences between
both D2-R isoforms such as interactions related to G-proteins [20–22], post-translation modification
and cell localization [11,23]. D2-R isoforms also indicate different in vivo functions, whereby D2L-R
primarily acts at postsynaptic and D2S-R in presynaptic dopaminergic transmissions [24,25]. Data
acquired on genetically engineered D2-R mouse model indicates additional evidence for different
roles of two isoforms in cognitive and motor functions [24], responsiveness to cocaine exposure [26],
and therapeutic effects of antipsychotic drugs [27]. Furthermore, they are expressed in the same
cell types with more abundant expression of the D2L-R isoform over D2S-R, but with differences in
their intracellular localization. While D2S-R is primarily localized on the plasma membrane (PM),
a substantial fraction of D2L-R is located intracellularly, especially in the perinuclear compartments
around the Golgi apparatus (GA) [14] and endoplasmic reticulum (ER) [23].
The D2-R is the most commonly studied dopamine receptor subtype since the majority of
antipsychotic drugs act as D2-R antagonists in the mesolimbic dopaminergic system [28]. As a primary
target for atypical and typical antipsychotic drugs and treatment of the Parkinson’s disease, many
of those agents can cause potentially life-threatening and severe side effects due to the promiscuous
activities against related D2-Rs [29]. Precisely because of this reason, it is necessary to be familiar with
the details of the dopamine receptor’s complex structure and functions.
3. Localization Differences Between D2S-R and D2L-R
D2-R isoforms localization is neither species nor tissue specific. They were found in different
tissues, but in highly variable ratios [25,30,31]. D2S-R is predominantly localized in the PM [14,22,32],
whereas an intracellular D2L-R reservoir has been reported in the primates brain [33] and several cell
lines [14,22,23].
The primary intracellular localization of the D2L-R in transiently transfected HEK-293, COS-7,
and HeLa is the ER [23], whereas in transfected NG108-15 cells intracellularly localized D2L-R is
predominantly co-localized with the GA matrix protein marker GM130 [14]. At the level of confocal
microscopy, higher proportions of D2L-R than D2S-R were retained intracellularly in heterologous cell
lines [22,23]. This finding could be due to the retention of overexpressed or incorrectly folded tagged
receptors in the ER. However, immunoelectron microscopy also revealed the predominant intracellular
localization of the D2L-R [34] in monkey dopaminergic neurons, and that these sites are cisterns of GA
and ER. Ligand-promoted recruitment of the D2L-R [35], D4-R [36] and other GPCRs, such as thrombin
receptors (PAR1 and PAR2), D1-Rs, and opioid receptors on the PM presented additional evidence for
the existence of functional, pre-existing intracellular stores (reviewed by Achour, 2008) [37].
N-terminal glycosylation of different GPCR’s has a vital role in cell surface receptor expression.
Mutations of potential N-terminal glycosylation sites found for D2-R (N5, N17, and N23) lead to
decreased surface expression for D2-R, showing their important role in receptor distribution [38].
Fishburn et al. performed studies regarding post-translational processing of the D2L-R and D2S-R
isoforms [39]. Three post-translational states were observed in both receptor isoforms: a newly
synthesized protein (35 kDa), a partially glycosylated product (45 kDa) and a fully glycosylated
receptor (70 kDa) [39].
A difference in the processing of the mature receptor was observed. The initial N-glycosylation
of the newly synthesized receptor protein occurred shortly after synthesis in both D2-R isoforms,
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suggesting that a rapid and efficient maturation towards partially glycosylated product occurs in
D2-R. However, a marked difference was observed in subsequent N-linked glycosylation, where D2L-R
showed slower production of fully glycosylated proteins in comparison to the D2S-R. Additionally,
they showed that 20% of the D2L-R remains in the partially processed form and never undergoes the
second stage of N-linked glycosylation.
4. Functional Differences between D2S-R and D2L-R
Identifying probable functional differences between D2S-R and D2L-R has been the subject of
numerous studies. Depending on the site of action and the effect on D2-R-mediated responses, isoforms
have different and likely antagonistic functions in vivo [24]. D2S-R is mainly a presynaptic receptor,
but at the postsynaptic level, it negatively modulates D1-R-dependent responses. In contrast, D2L-R is
found predominantly at postsynaptic sites where it acts synergistically with D1-Rs [24].
The location of the inclusion in ICL3 also led to the assumption that it may affect the specificity of
the interaction with G-proteins and the sequential activation of specific effector proteins.
Several studies have shown that structural differences between isoforms can determine the
specificity of interactions with G-proteins [10,40]. A recent study showed the preferential coupling
of both D2-R isoforms with G-proteins (Gi1 and Gi2), due to the differences in ICL3, which affect
receptor behavior [11,41]. Results obtained with the messenger gene construct controlled by the cAMP
response promoter suggest constitutive, i.e., agonist-independent D2L-R activity [42]. Studies with
D2-R knockout mice provided additional evidence for their diverse roles in motor and cognitive
functions [43], sensitivity to cocaine [44], and therapeutic/side effects of antipsychotic agents [45].
5. The ER Retention Motifs in GPCRs and Both D2-R Isoforms
The synthesis and transfer of newly formed proteins via secretory pathways from the ER to the
PM is a complex process involving different mechanisms and many additional proteins and motifs
that are important in protein interaction and enable their proper formation, quality control, selective
retention, and transport [46]. Mechanisms that regulate the secretory transport of GPCRs or their
transfer to the cell surface are poorly elucidated [47,48]. It is known that the interconnection of the
same or different GPCRs, homo- and heterodimerization, is essential in the transport of GPCRs in
families A and C, but not for representatives of family B on the PM [49]. Transfer of the protein to the
PM requires control of transport from the ER via the GA to the PM. This process is regulated by COPI
and COPII vesicles [50]. COPII-coated transfer vesicles serve anterograde transport from the ER to
GA, whilst transport between GA cisternae and retrograde transport from GA to ER takes place with
COPI-coated vesicles. Improperly synthesized proteins or those having exposed sequences encoding
motives for retention in the ER are transported retrogradely into the ER by COPI-coated vesicles [51].
Moreover, correctly folded proteins might be retained in the ER because they hold ER retention motifs,
which prevent their export from the ER. Three types of ER retention motifs have been identified in the
intracellular domains of various proteins: KDEL, KKXX, and RXR type motifs [46]. The presence of
specific conserved sequences, so-called ER retention signals, could be responsible for preventing D2-R
proteins from leaving the ER. Since the level of GPCR expression dictates the magnitude of cellular
responses elicited by a signal at the PM, which is the balance of elaborately regulated endocytic and
exocytic trafficking, it is crucial to know the motifs as well as the proteins involved in this interplay.
6. KDEL and KKXX Motifs
The KDEL motif is a short C-terminal retrieval signal (Lys-Asp-Glu-Leu) identified in ER luminal
chaperone proteins, such as immunoglobulin heavy chain-binding protein (BiP) and other soluble ER
resident proteins [20,52,53]. The KDEL receptor recognizes this motif in the post-ER compartments,
which mediates retrograde transport to the ER by COPI coatomer structures [54]. For the proper sorting
of cargo into COPI vesicles, a Ras-like small GTPase ADP-ribosylation factor 1 (ARF1) activation is
required [55]. ARFGAP1 activates ARF1 by hydrolysis of GTP to GDP [56]. Ligand binding on the
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luminal side of the KDEL receptor induces interaction with ARFGTP1 on the cytoplasmic side of
the receptor, resulting in the recruitment of ARFGTP1 from the cytosol to the PM leading to ARF1
activation [57].
In zebrafish D2-Rs and D3-Rs, the expression of gene Hsp47 was identified, which is an ER-resident
collagen-specific chaperone with a C-terminal KDEL retention motif and plays a fundamental role in
the folding, stability, and intracellular transport of procollagen triple helices [58].
The KDEL receptor cycles between the ER and the GA and its affinity for KDEL containing proteins
changes between these two compartments. Retrieval of proteins mediated by the KDEL receptor can
occur from different sites, ranging from early Golgi complex locations to trans Golgi networks [30].
In the GA, the KDEL receptor could associate with Gαo, one of the abundant Gα subunit and regulate
receptor trafficking through G-proteins [59].
In addition to KDEL, the di-lysine motif (KKXX), have been identified as retrieval signal, important
for recycling proteins from the GA back to the ER [60]. These signals are necessary for determining the
localization of modified secretory and PM proteins in the ER [30].
Type I integral membrane proteins, ERGIC53, and p24 family proteins contain di-lysine KKXX
motifs [46]. This carboxyl-terminal retrieval signal usually consists of two lysine residues on positions
-3 and -4 relative to the C-terminus, followed by any amino acid [61]. The KKXX signal is evolutionarily
conserved as it also appears in yeast [20]. Like KDEL, the KKXX motif also serves as a retrieval signal
for the transport of proteins from GA by COPI vesicles, although it binds directly with coatomer
structures and does not require a receptor [62].
7. RXR and RSRR Motifs
The RXR motif, and in some proteins, RSRR, has been found on different proteins where it
disables the exit of proteins from the ER. Initially, they were found in ion channels and also in several
GPCRs [46,63]. The first discovered of two arginine retention signals (the RXR and RSRR) are known to
be located at the C-terminal end of the Kir 6.2 potassium channel (RXR signal) and a GPCR representative,
the gamma-aminobutyric acid type B1 receptor (GABAB1; RSRR signal) [27]. The GABAB1 receptor
contains the C-terminal RXR type ER retention motif RSRR, which prevents protein release from the
ER. GABAB1 is functionally impaired in terms of ligand binding when expressed alone, whereas
GABAB2 is nonfunctional in its signaling properties. Only when co-expressed with GABAB2, GABAB1
receptor releases from the ER and translocates to the cell surface [27,64]. Upon co-expression, the RSRR
retention signal of GABAB1 is proposed to be masked by interaction of the C-terminus of both subunits
due to highly stable α coil-coil interactions. Therefore, GABAB1 and GABAB are functionally combined
of distinct subunits as obligatory constitutive heterodimers [27,64–66].
There are more examples of the RXR-type retention motif in GPCR receptors. A published study
showed that in the C-terminal end of the type 2c α-adrenergic receptor (α2C-AR), there is a set of
five arginine residues (RRRRR), which represent a possible retention signal of the ER type RXR [67].
The RXR-type retention motif has also been described in the ICL3 of the kainate receptor, which is a
ligand-dependent ion channel [68]. Disease-causing vasopressin type 2 receptors (V2R) mutations
are retained in different compartments of the early secretory pathway [69]. V2R mutants connected
to nephrogenic diabetes insipidus in the contrast with the wild-type V2R are less expressed on the
cell surface. Additionally, the D2-R RXR motifs have been revealed. In our study [70], we showed
that the evolutionarily conserved arginine cluster in the insert of ICL3 of D2L-R (R267-R269) acts as an
ER retention signal and is potentially crucial for anterograde trafficking of the D2-R and receptor PM
availability. However, we must take into account that ER exit is a highly regulated process and that
one motif is not responsible solely for it. Other proposed mechanisms involving interaction with the
ER-resident gatekeeper prenylated Rab acceptor 1 domain family member 3 (PRAF3) or other D2L-R
binding and interaction proteins, such as fatty acid-binding protein 3 (FABP3), which possibly bind to
29 AA in ICL3 in D2L-R may be included (Figure 1) [71].
Biomolecules 2020, 10, 1355 6 of 18
Additionally, the mutational analysis revealed that heteromers between the dopamine D2-R,
adenosine A2A and cannabinoid CB1 receptors are stabilized by electrostatic interactions between
arginine-rich motifs in the ICL3 of D2-R and A2A receptors and phosphorylated casein kinase 1/2 sites
in ICL3 and C-tail of the CB1 receptor, and the C-terminus of the A2A receptor [72]. The RXR-rich motif
in ICL3 of the D2-R is also involved in stabilizing electrostatic interactions with a di-glutamate motif in
the C-terminus of the serotonin 5-HT2A and D1-R [73,74].
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apoptosis response-4; PM-plasma membrane; PREB—prolactin regulatory element-binding protein; 
Rabex-5-Rabaptin-5 interacting protein; TRAPPC9—Trafficking protein particle complex subunit 9. 
8. ER Export Motifs in GPCRs and D2-R 
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receptors are recruited and packaged into ER-derived COPII-coated vesicles. Transport vesicles 
carrying cargo receptors then migrate from the ER to the ER-Golgi intermediate complex (ERGIC), 
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Figure 1. Motif and interaction partners’ differences between D2L-R and D2S-R. CaM—Ca2+-binding
protein calmodulin; CGAT—Chromaffin granule mine transporter; DAT—dopamine transporter;
FABP3-Fatty acid binding protein 3; FLN-A—filamin A; NMDA (NR2B)—NR2B subunit of the
NMDA glutamate (N-methyl-D-aspartate); NSF—N-ethylmaleimide-sensitive factor; Par-4—Prostate
apoptosis response-4; PM-plasma membrane; PREB—prolactin regulatory element-binding protein;
Rabex-5-Rabaptin-5 interacting protein; TRAPPC9—Trafficking protein particle complex subunit 9.
Likhite, N. et al. [75] use bioinformatics analysis to identify 583 RGG and RXR-type motifs in
GPCRs. Approximately 34% of those were conserved in human GPCRs within the ICL3 and could
serve as arginine methylat on motifs. The showed that R217 and R219 within the ICL3 N-terminal
end common to both D2-R isoforms serve as an arginine N-methyltransferase 5 (PRMT5) methylation
motif important for modulating receptor signaling [75]. This corroborates with R217 and R219 location
of within the Gα interaction domain (reviewed in [75]).
Furthermore, Table 1 summarizes selected motifs from the eukaryotic linear motif (ELM) [76]
resources, which are potentially involved in ER-GA trafficking of the D2-R. The experimentally
validated short linear motifs (SLiM) were manually curated after globular domain filtering, structural
filtering, and context filtering.
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Table 1. Motifs obtained from eukaryotic linear motif (ELM) bioinformatics analysis of type 2 dopamine receptor D2 (D2-R) sequences.
ELM Name
Instances
(Matched
Sequence)
AA
Position ELM Description Cell Compartment Pattern
Probability
(×103)
TRG_ER_diArg_1
RRRR
RRR
RRKR
RKRV
RRR
RRV
217–220
218–220
219–222
220–223
267–269
268–270
The di-Arg ER retention motif is defined by two
consecutive RR residues or with a single residue
insertion (RXR). The motif is completed by an
adjacent hydrophobic/arginine residue, which may
be on either side of the R pair.
ER membrane,
integral protein,
ER-GA transport vesicle
membrane,
ER membrane,
GA-ER transport vesicle
membrane, rough ER,
ER
([LIVMFYWPR]R[ˆY
FWDE]{0,1}R)|(R[ˆY
FWDE]{0,1}R[LIVM FYWPR])
5.37
CLV_NRD_NRD_1
RRK
RRV
RRA
RRK
FRK
219–221
268–270
274–276
360–362
433–435
N-Arg dibasic convertase (NRD/Nardilysin)
cleavage site (X-|-R-K or R-|-R-X).
extracellular,
GA,
cell surface
(.RK)|(RR[ˆKR]) 7.47
CLV_PCSK_FUR_1 RRRKRRKRV
217–221
219–223 Furin (PACE) cleavage site (R-X-[RK]-R-|-X).
extracellular,
GA,
GA membrane
R.[RK]R. 50.09
CLV_PCSK_KEX2_1
KRR
RRR
RRR
RRK
KRV
KRS
RRR
RRV
RRA
RRK
149–151
217–219
218–220
219–221
221–223
226–228
267–269
268–270
274–276
360–362
Yeast kexin 2 cleavage site (K-R-|-X or R-R-|-X).
extracellular,
GA [KR]R. 7.97
CLV_PCSK_PC1ET2_1
KRR
KRV
KRS
149–151
221–223
226–228
NEC1/NEC2 cleavage site (K-R-|-X).
extracellular,
GA,
GA membrane
KR. 3.90
CLV_PCSK_PC7_1
RYSSKRR
RRRRKRV
RVNTKRS
145–151
217–223
222–228
Proprotein convertase 7 (PC7, PCSK7) cleavage site
(R-X-X-X-[RK]-R-|-X).
extracellular,
GA,
GA membrane
R...[KR]R. 50.09
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Table 1. Cont.
ELM Name
Instances
(Matched
Sequence)
AA
Position ELM Description Cell Compartment Pattern
Probability
(×103)
CLV_PCSK_SKI1_1
KIAKI
KKATQ
RKAFL
KAFLK
336–340
369–373
434–438
435–439
Subtilisin/kexin isozyme-1 (SKI1) cleavage site
([RK]-X-[hydrophobic]-[LTKF]-|-X).
ER lumen,
ER
GA,
extracellular
[RK].[AILMFV][LTKF]. 6.82
LIG_deltaCOP1_diTrp_1 EWKF 99–105
Tryptophan-based motifs enable targeting of the
tethering and (dis)assembly factors to the
C-terminal mu homology domain (MHD) of the
coatomer subunit delta, delta-COP.
ER membrane
GA membrane,
COPI coated vesicle
membrane,
cytosol,
COPI vesicle coat,
transport vesicle
[DE]{1,3}.{0,2}W.{1,6}[WF] 50.10
LIG_LIR_Gen_1 EWKFSRI 99–105
Canonical LIR motif that binds to Atg8 protein
family members to mediate processes involved in
autophagy.
cytosol, cytoplasmic side of
late endosome membrane
[EDST].{0,2}[WFY]
[ˆRKPG][ˆPG][ILV] 3.06
LIG_LIR_Nem_3 EWKFSRITRYSPI
99–105
293–298
Nematode-specific variant of the canonical LIR
motif that binds to Atg8 protein family members to
mediate processes involved in autophagy.
cytosol, cytoplasmic side of
late endosome membrane [EDST].{0,2}[WFY]..[ILVFY] 6.36
MOD_N-GLC_1 EWKFSRITRYSPI
99–105
293–298
Generic motif for N-glycosylation. It was shown
that Trp, Asp, and Glu are uncommon before the
Ser/Thr position. Efficient glycosylation usually
occurs when ~60 residues or more separate the
glycosylation acceptor site from the C-terminus.
extracellular, GA, ER [EDST].{0,2}[WFY]..[ILVFY] 5.02
MOD_N-GLC_2 NEC 180–182
Atypical motif for N-glycosylation site. Examples
are Human CD69, which is uniquely glycosylated
at typical (Asn-X-Ser/Thr) and atypical (Asn-X-Cys)
motifs, beta protein C.
extracellular, GA, ER (N)[ˆP]C 29.7
TRG_ENDOCYTIC_2 YTAVYSPI
133–136
295–298
Tyrosine-based sorting signal responsible for the
interaction with mu subunit of AP (Adaptor
Protein) complex.
PM,
clathrin-coated endocytic
vesicle,
cytosol
Y.[LMVIF] 2.59
Legend: GA—Golgi apparatus; ER—endoplasmic reticulum; PM—plasma membrane.
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8. ER Export Motifs in GPCRs and D2-R
GPCRs originate in the ER, where they are synthesized, folded, and assembled. Properly folded
receptors are recruited and packaged into ER-derived COPII-coated vesicles. Transport vesicles carrying
cargo receptors then migrate from the ER to the ER-Golgi intermediate complex (ERGIC), the GA,
and the trans Golgi network (TGN). During their transport, receptors undergo post-translational
modifications (e.g., glycosylation). Mature receptors then move from the TGN to their destination at
the PM [77]. For this process, conserved sequences and motifs essential for the exit of GPCRs from
the ER are critical. Export from the ER is the first step in the intracellular trafficking of GPCRs These
motifs are found on the C- or N-terminal tail of the receptors and are therefore common to both D2-R
isoforms. A triple phenylalanine motif [F(X)3F(X)3F] [14] has been identified in the membrane-proximal
C-terminus of the D1-R that is required for receptor cell-surface expression [78]. However, no motifs
have yet been identified on the D2-R. A newly identified ER-membrane-associated protein, DRiP78,
binds to this motif, as described later.
9. D2-R Interaction Proteins (DRIPs)
More than 20 dopamine receptor-interacting membrane-associated or cytoplasmic D2-R interaction
proteins (DRIPs) are known and several of them bind the ICL3 of the D2-R [79]. Using the informational
spectrum method (ISM), a virtual spectroscopy method for investigating protein-protein interactions, the
analysis of known interaction partners of IC3 of D2-R [79] was performed as previously described [80,81]
and obtained the results presented in Table 2. ISM analysis of the IC3 D2-R interaction with protein
partners corroborates with published data (reviewed in [79]) (Table 2, Figure 1). However, in addition
to previously identified protein partners it has also been suggested that there are some new potential
interaction partners.
Among previously described interaction partners, the highest affinity for the interaction with
the D2-R was ascribed to N-methyl-D-aspartate (NMDA) receptor NR2B subunits. It was shown
that a distinct region within the first 32 AA of the D2-R ICL3 interacts with the NR2B and disrupts
the association of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with NR2B, reduces NR2B
phosphorylation at a CaMKII-sensitive site (Ser1303), and inhibits NMDA receptor-mediated currents
in medium-sized striatal neurons. The D2-R-NR2B interaction is therefore critical for modulating
NMDA receptor-mediated currents and behavioral responsiveness to cocaine [82]. The second
highest propensity for interaction with the D2-R was observed for prostate apoptosis response-4
(Par-4). Par-4 is a protein expressed in the nervous system, where it is known to be a regulatory
component in dopaminergic signaling. It is a mediator of neuronal degeneration, and is associated
with the pathogenesis of Alzheimer’s disease [83]. Par-4 directly interacts with the D2-R via the
calmodulin-binding motif in the ICL3. Furthermore, Par-4 constitutes a molecular link between
impaired dopaminergic signaling and depression [84]. The N-terminal segment of the D2-Rs and D3-R
was also shown to interact with neuronally enriched 4.1N protein; an interaction that contributes
to the localization and stability of D2-Rs at the neuronal PM [85]. Similarly, filamin-A (FLN-A) also
interacts with the N-terminal segment of the ICL3 of the D2-R and D3-R, and connects D-Rs with
some other GPCRs, such as rhodopsin and, metabotropic glutamate receptors to the cytoskeleton,
and therefore participate in their final subcellular localization [86]. The dopamine transporter (DAT)
is a membrane-spanning protein that facilitate the reuptake of extracellular dopamine to the cytosol
and is therefore, an essential target for cocaine, amphetamine, and some other drugs of abuse. One
study showed a direct interaction between the DAT and the ICL3 (I340-Q373) of both D2-R isoforms.
However, D2L-R is more capable of physically interacting with the DAT [87].
The Ca2+-binding protein calmodulin (CaM) binds to the N-terminal portion of the ICL3 of the D2L-R,
within an Arg-rich epitope (VLRRRRKRVN) that is also involved in the binding to Gi/o proteins and the
adenosine A2A receptor, with the formation of A2A-D2-R heteromers [88,89]. N-ethylmaleimide-sensitive
factor (NSF) is an ATPase and an essential part of the protein network responsible for different membrane
fusion events, including transport through the GA and exocytosis [90]. Using immunoprecipitation and
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in vitro binding assays, it has been shown that NSF binds to the ICL3 of D-R (F341-Q373) and has a
putative role in the interaction of D2-R and the Glu2 AMPA receptor [91]. Agonist stimulation of D2-R
promotes the formation of direct protein-protein interactions between the ICL3 of the D2-R and the ATPase
N-ethylmaleimide-sensitive factor (NSF). Spinophilin is F-actin and protein phosphatase-1-binding
protein with a single PDZ domain that was identified as a protein associated with the ICL3 region of
the D2-R. It is hypothesized to be necessary for establishing signaling complexes for dopaminergic
neurotransmission through D2-Rs by linking receptors to downstream signaling molecules and the actin
cytoskeleton [92].
Three additional hypothetical ICL3 D2-R interaction partners were suggested by ISM:
prolactin regulatory element-binding protein (PREB), chromaffin granule amine transporter (CGAT)
and trafficking protein particle complex subunit 9 (TRAPPC9). Among prospective partners,
CGAT displayed the highest affinity for interacting with the ICL3 D2-R, followed by TRAPPC9
and PREB. For all three prospective interaction partners we were unable to find experimental evidence
for the direct interaction with the ICL3 of the D2-R but only some indirect indication for their
involvement in dopamine synthesis, transport, or D2-R binding. PREB is an ubiquitously expressed
protein and, a member of the WD-repeat protein family, that acts as a transcriptional regulator and
suppresses the expression of the adiponectin gene [93], regulates prolactin (PRL) gene expression [94]
and functions as a transcriptional regulator of PRL promoter activity, and therefore might be involved
in thyrotropin-releasing hormone (TRH)-induced PRL gene transcription [95]. PRL gene expression
and secretion are regulated by various hormones and growth factors, including dopamine, epidermal
growth factor, and thyrotropin-releasing hormone (TRH) [95]. PREB is highly expressed in the anterior
pituitary. Prolactinomas are the most common pituitary tumors and are treated with the selective
dopamine D2-R agonist cabergoline [96]. Mutation of the PREB-binding site within the promoter
abrogated the ability of cabergoline to inhibit PRL promoter activity. The chromaffin granule amine
transporter (CGAT), also named the vesicular monoamine transporter 1 (VMAT1), is involved in
the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory
vesicles of neuroendocrine and endocrine cells. It has a positive impact on dopamine synthesis,
secretion, and transport to storage vesicles, which releases neurotransmitters into synapses as chemical
messages to postsynaptic neurons [97]. The pharmaceutical industry also targets VMATs for treating
hypertension, drug addiction, psychiatric disorders, Parkinson’s disease, and other neurological
disorders. The trafficking protein particle complex subunit 9 (TRAPPC9), also known as NIBP,
belongs to the TRAPPII multiprotein complex. TRAPPC9 is involved in vesicular trafficking from the
ER to the GA and promotes the activation of NFκB signaling. It is highly expressed in the postmitotic
neurons of the cerebral cortex [98].
To the best of our knowledge, only two proteins have been identified that specifically interact only
with the D2L-R i.e., 29 AA within its ICL3. These proteins are fatty acid-binding protein 3 (FABP3) [99]
and Rabaptin-5 interacting protein (Rabex-5) [23]. Fatty acid-binding protein 3 (FABP3), also named the
heart-type FABP (H-FAB), is one of the novel 29 AA insert binding protein on the position (G242-V270),
which also alters D2L-R function [99]. D2L-R, when activated with a ligand, is known to activate the
mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) pathways, which are
enhanced by FABP3 in FABP3-overexpressed cells, showing that FABP3 enhances D2L-R signaling [14].
A co-expression study of D2L-R and D2S-R with this protein in NG108-15 cells shows overexpression
and colocalization of endogenous FABP only with the D2L-R in the GA and ER but not in the PM [100].
Dysfunction of FABP3 protein binding to D2L-R was shown in FABP3 KO mice [100], which affects
emotional behavior, and is characteristic of neurodegenerative diseases such as schizophrenia and
Alzheimer’s disorder. These KO mice, which showed altered sensory, motor, and emotional behaviors,
also exhibited decreased methamphetamine-induced sensitization and enhanced haloperidol-induced
catalepsy due to D2-R dysfunction. Impaired FABP brain function was observed as an essential factor
in the perturbation of D2-R signaling [101]. Rabaptin-5 interacting protein (Rabex-5) was identified in
mouse brain lysates as another protein binding the 29 AA of D2L-R and has been shown to promote the
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early-endosome formation and Rab5 activation [71]. Both proteins are essential for prolonged D2L-R
mediated ERK signaling.
DRIPs have the propensity to bind to conserved motifs in receptors. For D1-R it was shown that
the ER-membrane-associated protein DRiP78 binds to a FXXXFXXXF motif in the C-terminus of D1-R
and other GPCRs. Overexpression or down-modulation of this putative two-TM domain protein leads
to ER retention of D1-Rs, reduced ligand binding, and impaired kinetics of receptor glycosylation [48].
This mechanism acts as a chaperone and may control PM receptor targeting without traveling to the
cell surface.
Some of the DRIPs are also possible “private” chaperones with other functions, escorting proteins
for D2L-R or proteins of the quality-control machinery involved in its retention within intracellular
compartments [37] and facilitating receptor cell surface expression by enabling their trafficking to
the PM. Pools of intracellular D1-R exist in renal tubular cells, and receptor recruitment to the PM
is independent of agonist activation elicited by the activation of cell surface receptors and via atrial
natriuretic peptide-dependent heterologous activation [102,103].
Table 2. The bioinformatics approach-informational spectrum method (ISM) analysis of interaction
partners of the third cytoplasmic loop (ICL3) of the D2-R. A lower signal to noise S/N ratio suggests a
lower interaction affinity between tested protein partners.
Interaction Partner S/N Ratio Function Reference
Glutamate, NMDA
(NR2B) 62.39 ionotropic glutamate receptor Liu, X.Y. et al. (2006) [82]
Par-4 48.63 regulatory component in dopaminesignaling
Guo, Q. et al. (1998) [83]
Park, S.K. et al. (2005) [84]
Protein 4.1N 38.61 membrane-cytoskeleton adaptor Binda, A.V. et al. (2002) [85]
FLN-A 26.65 actin binding protein Lin, R. et al. (2001) [86]
DAT 20.29 facilitating reuptake of extracellulardopamine back in the cytosol Lee, F.J. et al. (2007) [87]
Gα i/z/o 17.85 binding GPCRs
CaM 13.36 intermediate calcium-bindingmessenger Navarro, G. et al. (2009) [88]
NSF 13.03 ATPase Hanson, P.I. et. al. (1995) [90]Zou S. et al. (2005) [91]
Spinophilin 12.14 F-actin and proteinphosphatase-1-binding protein Smith, F.D. et al. (1999) [92]
Predicted
Interaction Partner 12.14
CGAT 19.90 involved in the transport of biogenicmonoamines
TRAPPC9 19.73 involved in vesicular trafficking fromER to GA
PREB 18.78 transcriptional regulator
Legend: Glutamate, NMDA (NR2B)—NR2B subunit of the NMDA glutamate receptor (N-methyl-D-aspartate);
FLN-A—filamin-A; Par-4—prostate apoptosis response-4; DAT—dopamine transporter; CGAT—chromaffin
granule amine transporter; TRAPPC9—trafficking protein particle complex subunit 9; PREB—prolactin regulatory
element-binding protein; NSF—N-ethylmaleimide-sensitive factor; CaM—Ca2+-binding protein calmodulin.
10. Interaction with ER-Resident Gatekeeper Proteins
ER gatekeeper proteins tightly control receptor cell-surface export. GTRAP3-18, an integral ER
membrane protein, was introduced as a protein both in vivo and in vitro, and is dynamically induced
by retinoic acid and inhibits the activity of EAAC1 in a dose dependent manner. GTRAP3-18 forms
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an oligomeric complex with D2-R before exiting the ER, increasing the population of high-mannose
oligosaccharide state proteins, and restricting its subcellular localization to the ER [104]. There is
evidence that the specific gatekeeper protein PRAF2 binds to subunit GABA1 of the GABAB receptor
and prevents its progression in the biosynthetic pathway [47]. Dupre, J.D. et al. showed that one of
the ER-resident proteins, which is known to regulate trafficking via a FXXXFXXXF motif of D-Rs and
interact mostly with the Gγ subunit and not Gα or Gβ subunits in HEK-293 cells, is dopamine-receptor
interaction protein 78 (DRiP78) [105]. Another ER-gatekeeper candidate of the D2-D3 heterodimer is an
activator of G protein signaling 3 (AGS3), which binds to GiαGDP and inhibits GDP dissociation in the
prefrontal cortex during late withdrawal from repeated cocaine administration. However, this actual
mechanism in D2-R signaling is still unknown [106]. In familiar, as well as in sporadic Parkinson’s
disease, a mutation in the leucine-reach repeat kinase 2 gene (LRRK2) represents the most frequent
genetic cause of disease. LRRK2 is a member of the Roco superfamily of proteins, a novel multi-domain
family of Ras-like G-proteins, involved in vesicle-mediated transport to the cell membrane. Because
LRRK2 could affect D2-R turnover by decreasing this rate of trafficking from the GA to the CM,
the LRRK2 could have an essential function in one of the possible retention mechanisms [107].
11. Clinical Relevance
This review examines the role of different types of conserved retention motifs and DRIPs on
D2-R and roles in routing regulation. The impact of both is of high importance for the physiological
functions of D2L-R and its export trafficking and precise localization in the cell. Defective transport of
D2L-R, as well as many other GPCRs from the ER to the cell surface, is a highly regulated, dynamic
process and is associated with the pathogenesis of a variety of human diseases, therefore advances in
our understanding of GPCR export. Thus, the secretory pathway and its role in proper cell function
are of high importance.
So far, we are not aware of any known mutation in the 29 AA region that would be associated
with a disease. No variant of D2L-R has been linked or associated with schizophrenia, substance abuse,
or alcoholism, including the most extensively investigated Ser311Cys polymorphisms of the D2-R gene.
In vitro studies showed that the Cys311-type D2-R impairs dopamine-induced sequestration, which
appears to be consistent with the dopamine hypothesis [108]. A naturally occurring synonymous
mutation of the human D2-R gene (C957T, P319P) is postulated to correlate with the schizophrenia
phenotype, and was shown to markedly change mRNA stability via changes in mRNA secondary
structure and reduced dopamine-induced up-regulation of D2-R expression [109]. We also conducted a
GPCR database (GPCRdb) search to find additional mutants of the D2-R and presented them in Table 3.
Table 3. A summary of mutations within the ICL3 of the D2-R (source: G protein-coupled receptor
(GPCR) database (GPCRdb); http://gpcrdb.org/mutations/render).
Receptor AA Residue Location Mutation Reference
drd2_human 249 ICL3 D => V Guiramand, J. et al. (1995) [110]
drd2_human 264 ICL3 P => G Guiramand, J. et al. (1995) [110]
drd2_human 310 ICL3 P => S Kaiser, R. et al. (2003) [111]
drd2_human 311 ICL3 S => C Kaiser, R. et al. (2003) [111]
drd2_human 311 ICL3 S => C Goldman D et al. (1997) [112]
drd2_mouse 251 ICL3 K => V Guiramand, J. et al. (1995) [110]
drd2_mouse 271 ICL3 D => V Guiramand, J. et al. (1995) [110]
drd2_rat 233 ICL3 R => G Senogles, SE. et al. (2004) [113]
drd2_rat 234 ICL3 A => T Senogles, SE. et al. (2004) [113]
We have not found additional mutations located within the insert (AA 241–270). Further
elucidation of the regulatory mechanism underlying GPCR export trafficking may provide an essential
foundation for developing new therapeutic strategies in treating diseases.
Biomolecules 2020, 10, 1355 13 of 18
The described differences in the evolutionarily preserved region within the 29 AA insertion in the
ICL3 of D2L-R influences the regulation of D2L-R cellular trafficking. A thorough search through motifs
showed a conserved arginine cluster within the 29-AA insert of ICL3 of the D2L-R, which appears
to be the ER retention signal. Identifying possible candidates for DRIPs may also reveal “private”
chaperones, which often display different functions or escort proteins for D2L-R or proteins of the
quality-control machinery that play a role in GPCR retention within intracellular compartments. We
speculate that other specific retention mechanisms for D2L-R exist. Thus, improving our knowledge of
the routing regulation of these critical receptors will probably elicit the development of new therapeutic
approaches in controlling the targeting of D2L-R at the PM.
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